Novartis Sp ADR (NVS)
$108.46
0.46 (0.42%)
NVS Stock Quote Delayed 30 Minutes
Biggest Movers in Healthcare Stocks Now – PCRX HALO TEVA NVS
Healthcare stocks advanced broadly 0.8% on Wall Street so far on Monday. NASDAQ:PCRX, NASDAQ:HALO, NYSE:TEVA, NYSE:NVS, NASDAQ:ALNY, NYSE:WX, NASDAQ:BIIB, NASDAQ:NPSP, NASDAQ:ISIS, NASDAQ:INCY, NASDAQ:MNKD, NYSE:PBYI, NASDAQ:CLVS, NASDAQ:PODD, NASDAQ:ARIA, NASDAQ:MYL, NYSE:RDY, NASDAQ:CLDX, NYSE:SNN, NASDAQ:XLRN
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$108.02
Market Cap
215.13B
PE Ratio
18.48
EPS
5.87
Volume (Avg. Vol.)
1.84M
Day's Range
$107.51 - $109.04
52-Week Range
$92.35 - $120.92
Dividend & Yield
$3.74 (3.45%)
NVS Stock Predictions, Articles, and Novartis Sp ADR News
3 Super-Cheap ETFs to Buy Now
One of the best ways to supercharge your profits over the long-term is to focus on low-cost ETFs, which help you keep more returns.
If Not Amgen, Who’s Next in Line to Buy Onyx?
A few larger players could make attractive suitors for Onyx Pharmaceuticals and its cancer drugs, but the key is whether they'll trump an already frothy bid
15 Dividend Stocks to Buy on the Cheap
Here are 15 dividend stocks that I find a great value today based on our fundamental analysis. All provide great yields and solid growth potential
Bulls vs. Bears: Can Biogen Keep Booming?
Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments.
India Drops Patent Bomb on Novartis
India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma.
The Best and Worst Mutual Funds of Q1 2013
Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind.
How to Play Today’s All-Too-Familiar Market
Like a year ago, the bulls are snorting wildly ... and the dumb money is buying while smart money sells. It's safe to assume that a solid correction is coming.
4 Pharmaceutical Stocks to Buy Now
This week, four Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
Big Pharma: 2012-13’s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.
4 Pharmaceutical Stocks to Buy Now
The grades of four Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
4 Attractive Biopharma Stocks of All Sizes
Biopharma is a high-growth niche in a defensive sector, but you need to balance risk with reward. Here are four hot biopharma stocks of different sizes.
4 Pharmaceutical Stocks to Buy Now
Four Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
Novartis Touts Pipeline of Blockbuster Drugs
Novartis says that it could produce 14 or more top-selling new drugs over the next five years as it expands its pipeline of new medications.
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.
5 Pharmaceutical Stocks to Buy Now
This week, five Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
The 10 Biggest, Baddest ETFs on Wall Street
If you’re an investor with just a small nest egg looking to tap into the wealth of Wall Street, consider these 10 top ETFs as a place to start.
7 Pharmaceutical Stocks to Buy Now
The grades of seven Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
